ArticleRheumatology and immunology research2025
Reevaluating risk assessment in connective tissue disease-associated pulmonary arterial hypertension: The prognostic superiority of stroke volume index.
Article in Rheumatology and immunology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the prognostic value of stroke volume index (SVI) compared to cardiac index (CI) in risk stratification and outcome prediction in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH). Methods: We performed a retrospective analysis of patients diagnosed with CTD-PAH through right heart catheterization (RHC) from two Chinese medical centers. This retrospective study analyzed 206 CTD-PAH patients, with risk stratification performed using the 2018 World Symposia on Pulmonary Hypertension (WSPH) framework. Restricted cubic splines (RCS) and log-rank tests were utilized to identify the optimal SVI cutof values for categorizing patients into low-, intermediate-, and high-risk groups. Kaplan-Meier (KM) curves were used to analyze survival rates and event-free survival. Receiver operating characteristic (ROC) analysis was used to assess the predictive accuracy of diferent models for prognostic outcomes. Results: SVI was categorized into low-risk (SVI ≥ 33.35 mL/m Conclusion: SVI enhances risk stratification and prognosis prediction in CTD-PAH by efectively distinguishing patients at higher risk for adverse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.